← All drugs built on NIH-funded research

Stealth Biotherapeutics · Elamipretide Hydrochloride

Forzinity: patented from NIH-funded research

Cornell University reported a patent on this drug to NIH as an invention made with NIH grant money. Stealth Biotherapeutics lists it with the FDA as protecting Forzinity.
Patent reported to NIH as grant-funded

Medicare paid, 2024

—

before rebates

Medicare, 2020–2024

$0

Medicaid paid, 2024

—

before rebates

NIH grants behind the patents

$11M

whole-grant totals, not the drug's cost

The public record, link by link

  1. 1 · Public money

    NIH grant to Weill Medical Coll of Cornell University, $11M in all.

  2. 2 · Patent

    7576061, reported to NIH under P01DA008924.

  3. 3 · FDA approval

    Approved Sep 19, 2025, held by Stealth Biotherapeutics (NDA 215244).

  4. 4 · Public pays

    Not yet in the Medicare or Medicaid spending files, which run to 2024.

The grants

Totals are everything NIH paid on each grant since 1985. A grant usually funded more than this one invention.
GrantResearchYearsNIH paid
P01DA008924

NIDA

SYSTEMICALLY-ACTIVE OPIOID PEPTIDE ANALOGS

Weill Medical Coll of Cornell University

1994–2007$11M

The patents

Patents the FDA lists for this drug that were also reported to NIH as grant-funded inventions.
  • US 7576061

    Methods for Preventing Mitochondrial Permeability Transition

    Reported by Cornell University

    FDA-listed expiry Jan 20, 2027

Stealth Biotherapeutics's side

Drug makers pay for the clinical trials that take a compound from the lab to FDA approval, and they often license the patent from the university and pay royalties on sales. Those terms are not public. The FDA's approval records for Forzinity are linked above, and Stealth Biotherapeutics's page shows its other drugs on this list. If Stealth Biotherapeutics wants to add its account, we will publish it here.

How this is built. Universities and companies that use NIH grants must report the inventions those grants produce to NIH, under the Bayh-Dole Act. NIH publishes the patent numbers and the grants they were reported under. We match those patents to the patents drug makers list with the FDA for each approved drug (the Orange Book), then add what Medicare Part D, Part B and Medicaid paid for each drug. Only patents still listed with the FDA appear, so drugs whose patents have expired drop out, and biologics, which the Orange Book does not cover, are not here yet.

What the numbers mean. "NIH grants" is everything NIH paid out on the grants a patent was reported under, from 1985 on. A grant usually paid for more than the one invention, so it is not the cost of the drug. Medicare and Medicaid figures are gross spending before the rebates drug makers pay back, which are confidential. Companies also paid for the clinical trials that took these drugs to approval; each drug page links the company's own filings.

Sources: NIH RePORTER patents reported under NIH grants (from iEdison); NIH RePORTER project funding; FDA Orange Book patent and product files; Medicare Part D Spending by Drug; Medicare Part B Spending by Drug; Medicaid Spending by Drug. Updated 2026-11-05.